Huey McDaniel
Endocrinology, Diabetes & Metabolism · Mobile, ALNPI 1619916277
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 534 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,261 and has fallen 98.2% since, to $41 in 2025.
Across 534 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$918
- Lilly USA, LLC$894
- Boehringer Ingelheim$572
- Sanofi-aventis U.S. LLC$504
- Merck$413
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,09499%
- Education$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 93 | $1,187 |
| AstraZeneca | 52 | $918 |
| Lilly USA, LLC | 58 | $894 |
| Boehringer Ingelheim | 35 | $572 |
| Sanofi-aventis U.S. LLC | 32 | $504 |
| Merck | 32 | $413 |
| Amgen | 26 | $340 |
| Antares Pharma, Inc. | 18 | $335 |
| Xeris Pharmaceuticals, Inc. | 14 | $269 |
| Dexcom, Inc. | 24 | $249 |
| AbbVie | 15 | $248 |
| BD | 12 | $246 |
| Corcept Therapeutics | 14 | $238 |
| Johnson & Johnson | 21 | $236 |
| Abbott | 10 | $214 |
| Amarin Pharma, Inc. | 10 | $180 |
| Clarus Therapeutics Inc. | 12 | $158 |
| Boston Scientific | 1 | $119 |
| Radius Health, Inc. | 7 | $117 |
| Insulet Corporation | 6 | $117 |
| Medtronic(2 entities) | 7 | $110 |
| Mannkind Corporation | 6 | $86 |
| Novartis | 4 | $79 |
| Bayer | 5 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Eisai Inc. | 3 | $44 |
| Tactile Systems Technology Inc | 1 | $41 |
| Ultragenyx Pharmaceutical Inc. | 3 | $40 |
| Shire North American Group Inc | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Rochester Medical Corporation | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Pfizer | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VARITHENA$119
How this compares
$8,217 in reported general payments places this provider in the 55th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Other endocrinology, diabetes & metabolism in Mobile
- Wilburn BoltonMobile$52K
- Anita KemmerlyMobile$13K
- Michael DavisMobile$12K
- Heather FishelMobile$11K
- Michael GalitzMobile$10K
- Jocelyn HewittMobile$9K
- Stephen DavisMobile$7K
- Ross del FierroMobile$6K
- Jessica BhathalMobile$6K
- Neil SchaffnerOpelika$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.